Studienamn med attityd – viktigare än man kan tro

Ironman, T-rex, Star-trec. Popcorn, Proper, Scout. Nej, det handlar varken om fantasyfilmer eller hundnamn. Utan om benämningar på pågående cancerstudier i Sverige.

Anna Törner: Yes, I Am Sick, But Not Weak

”People often say that someone who is ill only has one wish—to get better. But I think that is not true. Someone who is ill also longs to be understood, to be r...

The investor: “The major common diseases are hot again”

She has previously been voted Investor of the Year and will now be moderating The Future of Swedish & Danish Life Science congress. We check the temperature of ...

Danish biotech to buy struggling American oncology company

Danish drugmaker Pharmacosmos has agreed to acquire American pharmaceutical company G1 Therapeutics in a deal that amounts to 405 million dollars.

Italian pharmaceutical company buys rights to immunotherapy from Sanofi

Italy's Recordati buys the rights to a treatment for the rare autoimmune disease cold agglutinin disease (CAD).

Optimize Your Visibility

ZEISS presents our newest VersaXRM® 730 3D X-ray microscope.

AI-Driven Microscopy Image Analysis in Pharma and Biotech

Extract breakthrough discoveries from large, complex data sets.

New Horizons in Biologics & Bioprocessing: Copenhagen 2026

A small thing that can solve your problems

If you are in need of a compact valve. Look no further! We have the VOVK

Norwegian cancer research companies merge

The Norwegian companies Ultimovacs and Zelluna Immunotherapy plan to merge. At the same time, it is made clear that Ultimovacs' CEO is leaving the company.

Lonza

Advancing 3D Culture Imaging: Insights from Academia, Biotech, and Pharma

Webinar | March 13, 2024, 12 PM EST.

RegSmart Life Science AB

Aurevia

WuXi AppTec, UK Ltd

Medicon Valley Alliance

Are you ready for EMC 2024?

Visit ZEISS at Europe’s largest Event dedicated to Microscopy and Imaging.

Mercodia AB

Truly Labs AB

Galderma

SGS Fimko Ltd.

MSD discontinues two Keytruda trials

MSD has stopped two late-stage trials that tested its blockbuster immunotherapy Keytruda as a treatment for skin and lung cancer.

JMP Statistical Discovery

QPS Netherlands B.V